Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Budesonide / formoterol fumarate (SYMBICORT) Clear all
Completed Phase 3 Interventional Results available

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

NCT00419952
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
122
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 119 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 10, 2026, 1:19 AM EDT
Terminated Phase 4 Interventional Results available

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo

NCT01760304
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Budesonide / Formoterol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)

NCT01290874
View directory record Official record
Conditions
Asthma
Interventions
Tiotropium, Salmeterol, Formoterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
1,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Jacksonville, Florida • Marietta, Georgia • Newton, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

NCT05755906
View directory record Official record
Conditions
Asthma
Interventions
BFF MDI 160/9.6 μg BID (320/19.2μg/day), BD MDI 160 μg BID (320 μg/day)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
63
States / cities
Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Not applicable Interventional Results available

Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations

NCT01218399
View directory record Official record
Conditions
Asthma
Interventions
Symbicort
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

NCT01360021
View directory record Official record
Conditions
Asthma
Interventions
Symbicort, Budesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

NCT02495168
View directory record Official record
Conditions
Asthma
Interventions
Generic Budesonide/Formoterol Fumarate Dihydrate, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate), Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Surprise, Arizona • Huntington Beach, California • San Jose, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

NCT01980615
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Inhaled BGF (PT010) Dose 1, Inhaled BGF (PT010) Dose 2, Inhaled BGF (PT010) Dose 3, Inhaled GFF (PT003), Inhaled Symbicort Dose 1, Inhaled Symbicort Dose 2
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

NCT00419757
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Anaheim, California • Chula Vista, California • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2012 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Personalized Treatment Algorithms for Difficult-to-treat Asthma

NCT04179461
View directory record Official record
Conditions
Asthma in Children
Interventions
Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

NCT00206154
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
143
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478683
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

NCT00449501
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
46
States / cities
Muscle Shoals, Alabama • Little Rock, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

NCT03015259
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/Formoterol fumarate dihydrate, Symbicort, Placebo
Drug
Lead sponsor
Kindeva Drug Delivery
Industry
Eligibility
18 Years and older
Enrollment
1,762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

NCT01854047
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 10, 2026, 1:19 AM EDT
Completed No phase listed Observational

Replication of the D58 Asthma Trial in Healthcare Claims Data

NCT04892732
View directory record Official record
Conditions
Asthma
Interventions
Budesonide, Budesonide-Formoterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
12 Years to 120 Years
Enrollment
66,581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 10, 2026, 1:19 AM EDT
Not listed Phase 3 Interventional

Effect of Symbicort on Sleep Quality in Patients With Emphysema

NCT01602523
View directory record Official record
Conditions
Emphysema, Poor Sleep Quality
Interventions
Budesonide/formoterol, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2012 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

NCT00419744
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
92
States / cities
Jasper, Alabama • Mobile, Alabama • Tucson, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 10, 2026, 1:19 AM EDT
Not listed Phase 4 Interventional

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

NCT00867737
View directory record Official record
Conditions
Asthma
Interventions
Advair HFA MDI 115/21, Symbicort 160/4.5 pMDI
Drug
Lead sponsor
Allergy and Asthma Center of El Paso
Other
Eligibility
12 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Not applicable Interventional Results available

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

NCT01117116
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate and salmeterol, budesonide and formoterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

NCT02497001
View directory record Official record
Conditions
COPD
Interventions
BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg, Symbicort® Turbuhaler® (TBH) Inhalation Powder
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
63
States / cities
Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 3 Interventional Results available

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

NCT05202262
View directory record Official record
Conditions
Asthma
Interventions
BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BD MDI 320 μg, Open-label Symbicort TBH 320/9 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
66
States / cities
Chandler, Arizona • Tucson, Arizona • Bakersfield, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 10, 2026, 1:19 AM EDT
Terminated Phase 4 Interventional Results available

Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma

NCT01070888
View directory record Official record
Conditions
Exercise Induced Asthma
Interventions
Budesonide/Formoterol, Budesonide
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 10, 2026, 1:19 AM EDT
Completed Phase 1Phase 2 Interventional

Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers

NCT05689983
View directory record Official record
Conditions
Asthma in Children, Nonadherence, Medication
Interventions
Maintenance ICS and Symptom Driven SABA, Symptom-driven budesonide/formoterol combination
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 10, 2026, 1:19 AM EDT